A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

ClinicalTrials.gov ID

NCT05980806

Lead Sponsor

Karyopharm Therapeutics IncINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

58Estimated

Last Update Posted

Feb 12, 2026Actual

Start Date

Apr 22, 2024Actual

Primary Completion Date

Jun 2027Estimated

Completion Date

Oct 2028Estimated

Official Title

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Brief Summary

The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.

• Myelofibrosis
• Moderate Thrombocytopenia
• Mild Thrombocytopenia

• Selinexor 60 mg
• Selinexor 40 mg
• Ruxolitinib
• Pacritinib
• Momelotinib

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Key Inclusion Criteria:

• A diagnosis of MF or post-ET or post-PV MF according to the 2016 World Health Organization (WHO) classification of MPN, confirmed by the most recent local pathology report
• Measurable splenomegaly during the screening period as demonstrated by spleen volume of greater than or equal to (>=) 450 cubic square centimeter (cm^3) by MRI or CT scan (results from MRI or CT imaging performed within 28 days prior to C1D1 are acceptable)
• DIPSS risk category of intermediate-1 with symptoms, or intermediate-2, or high-risk
• ECOG Performance Status less than or equal to (<=) 2
• Platelet count of greater than or equal to (>=) 50 x 10^9/L without platelet transfusion within 7 days prior to the first dose of selinexor
• Absolute neutrophil count (ANC) >=1.0 × 10^9/L without need for growth factors within 7 days prior to the first dose of selinexor
• Adequate liver function as defined by the following: aspartate transaminase (AST) and alanine transaminase (ALT) <= 2.5 × upper limit normal (ULN) and serum total bilirubin <= 3×ULN
• Calculated creatinine clearance (CrCl) greater than (>) 15 milliliter per minute (mL/min) based on the Cockcroft and Gault formula
• Active symptoms of MF as determined by presence of at least 2 symptoms with an average score >= 5 or total score of >= 12 at screening (at least 5 of 7 consecutive days immediately preceding C1D1) using the MFSAF V4.0
• Must provide bone marrow biopsy samples (samples obtained up to 3 months prior to C1D1 are permitted) at screening and during the study
• Currently not eligible for stem cell transplantation
• Must be willing to complete the MFSAF V4.0 daily during the study for evaluating the symptom response (i.e., TSS50)

Key Exclusion Criteria:

• More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase)
• Previous treatment with JAK inhibitors for MF
• Previous treatment with selinexor or other XPO1 inhibitors
• Females who are pregnant or lactating
• Prior splenectomy, splenic radiation, or a splenic embolization within 6 months prior to C1D1
• History of myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG), cerebrovascular accident (transient ischemic attack [TIA]), ventricular arrhythmias, congestive heart failure class > 2 per New York Heart Association (NYHA) within 6 months of C1D1
• Unable to tolerate two forms of antiemetics prior to each dose for the first two cycles

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Karyopharm Therapeutics IncINDUSTRY

lindsay.magura@duke.edu919-684-8964

gerdsa@ccf.org216-445-9840

PBose@mdanderson.org(713) 792-7747

dominiek.mazure@uzgent.be+32 9 332 21 25

timothy.devos@uzleuven.be+32 (0) 16 346880

antonin.hlusi@fnol.cz+420 588443296

g.etienne@bordeaux.unicancer.fr+33 556 333 333

jean-jacques.kiladjian@sls.aphp.fr33142499429

lise.willems@aphp.fr+33 1 58 41 26 70

Stefanie.Groepper@vkkd-kliniken.de+49 (0)211 / 4400 2501

Carl.Crodel@med.uni-jena.de+49 3641 9324236

ppanayi@med.uoa.gr+30 210-746-2183

nagy.zsolt@med.semmelweis-univ.hu+36 1-2101500

n_lavi@rambam.health.gov.il+972 4 777 3520

elenahi@clalit.org.il972 54 4654625

roberto.lemoli@unige.it+39 0103538978

federica.gigli@ieo.it+39 02574891

e.rumi@smatteo.pv.it+39 0382-5011

lrigacci@scamilloforlanini.rm.it39 06 58 70 3494

abeeker@spaarnegasthuis.nl+31 232245811

michal.kwiatek@aidport.pl+ 48 793 602 210

gabriex2001@yahoo.it744150652

diaconu_luminita@yahoo.com+40 251-307-530

c_danaila@yahoo.com40722565781

jwcheong70@yuhs.ac+82 222285810

hojinja@hanmail.net+8251-240-7472; +8251-240-7473

bxicoy@iconcologia.net+34 934978987

victor.higuero@salud-juntaex.es+34 927 621 540

angona.figueras@iconcologia.net+34 972225843

hsinanhou@ntu.edu.tw886972653089 ext. #266678

horng@cgmh.org.tw"+886 0975-368-107

• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389

  Active, not recruitingInterventionalPhase 3Updated Apr 9, 2026
• Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

  NCT03627403

  TerminatedInterventionalPhase 2Updated Jun 8, 2026
• Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

  NCT07750574

  Not yet recruitingInterventionalPhase 2Updated Aug 10, 2026
• Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

  NCT05280509

  RecruitingInterventionalPhase 1Phase 2Updated Feb 21, 2023
• A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

  NCT05037760

  RecruitingInterventionalPhase 2Updated Feb 5, 2026
• Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

  NCT04878003

  Unknown statusInterventionalPhase 2Updated May 9, 2022